Exelixis, Inc.
EXEL
株式のランク
#1430
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer,... Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
株価
$61.84
最終同期: 2026-10-16
時価総額
$15.54B
変化（1日）
-1.58%
変化（1年）
57.55%
国
US
取引 Exelixis, Inc. (EXEL)
カテゴリー
Healthcare
Exelixis, Inc.（EXEL）の営業利益率
October 2026 時点の営業利益率 TTM: 39.88%
Exelixis, Inc. の最新の財務報告と株価によると、現在の営業利益率（TTM）は 39.88% です。2025 年末時点では 27.88% でした。
Exelixis, Inc. の営業利益率の履歴（2000 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | 39.88% | 43.04% |
| 2025 | 27.88% | 198.50% |
| 2023 | 9.34% | -25.34% |
| 2022 | 12.51% | -37.39% |
| 2021 | 19.98% | -47.67% |
| 2020 | 38.18% | -25.72% |
| 2018 | 51.40% | 40.17% |
| 2017 | 36.67% | -349.63% |
| 2016 | -14.69% | -98.36% |
| 2014 | -893.86% | 39.55% |
| 2013 | -640.54% | 148.24% |
| 2012 | -258.03% | -934.78% |
| 2011 | 30.91% | -162.58% |
| 2010 | -49.39% | -67.54% |
| 2009 | -152.14% | 9.93% |
| 2007 | -138.40% | 7.74% |
| 2006 | -128.46% | 3.81% |
| 2005 | -123.74% | -51.62% |
| 2004 | -255.79% | 36.95% |
| 2003 | -186.77% | -5.74% |
| 2002 | -198.15% | 7.88% |
| 2001 | -183.67% | 6.09% |
| 2000 | -173.12% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 38.59% | -99.03% |
US
|
|
| -149.01% | -103.74% |
US
|
|
| 25.57% | -99.36% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.28% |
NL
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。